UCSF
/ Biophysical Society Symposium
Honoring
Peter
A. Kollman
Molecular
Simulations in Structural Biology and Drug Discovery
UCSF
Laurel Heights Conference Center
3333
California Street
San
Francisco, CA 94118
February
21-22, 2002
On February 21-22,
2002, scientists from academia and industry met in San Francisco
to honor the memory of Peter
Kollman and to discuss molecular simulations in structural biology
and drug discovery. Organized by Professors Ken
Dill, Thomas Cheatham,
and Kennie Merz, the symposium
brought together three hundred participants at the University of California
San Francisco. Professor Kollman, whose work profoundly influenced computational
chemistry, structural biology and drug discovery, was Professor of Chemistry
and Pharmaceutical Chemistry at UCSF from 1971 to 2001. The meeting was
sponsored by the UCSF
Department
of Pharmaceutical Chemistry and the UCSF Molecular
Design Institute. It was co-sponsored by the Biophysical
Society as a satellite meeting of the Year 2002 Annual Biophysical
Society Meeting.
SPEAKERS
AND CHAIRS
| Lucia
Banci,
University of Florence |
Stephen
Harvey,
University of Alabama |
| David
Beveridge,
Wesleyan University |
Ken
Houk,
UCLA |
| Frank Brown,
R.W.
Johnson Pharmaceutical Research Institute |
William
Jorgensen,
Yale University |
| Jim
Caldwell, UCSF |
Irwin
Kuntz, UCSF |
| David
Case,
Scripps Research Institute |
Richard
Lavery, CNRS |
| Thomas
Cheatham,
University of Utah |
Michael
Levitt,
Stanford University |
| Piotr Cieplak, Accelrys |
J.
Andrew McCammon, UCSD |
| Wendy Cornell, Novartis |
Kennie
Merz,Pennsylvania State University |
| Valerie
Daggett,
University of Washington |
Vijay
Pande, Stanford University |
| Tom
Darden,
NIH, NIEHS |
David Pearlman,
Vertex
Pharmaceuticals |
| Ken
Dill,
UCSF |
Jed Pitera, IBM
Almaden |
| Yong
Duan, University of Delaware |
Shashi Rao, Accelrys |
| Ron
Elber,
Cornell University |
Celia
Schiffer, University of Massachusetts |
| Tom
Ferrin, UCSF |
Tamar
Schlick,New York University |
| Richard
Friesner,
Columbia University |
Carlos
Simmerling,SUNY Stony Brook |
| Jiali
Gao,
University of Minnesota |
David Spellmeyer,
Signature
Bioscience |
| Peter Grootenhuis,
Bristol-Myers
Squibb Pharmaceutical Research Laboratories |
Terry Stouch,
Bristol-Myers
Squibb |
| Jean-Marie Guenot, Atlas
Venture |
Wilfred
van Gunsteren,
ETH Switzerland |
MEETING PROGRAM
The two day meeting, with presentations,
poster sessions and a dinner on Thursday evening, was held at the UCSF
Laurel Heights Conference Center.
Link here
to the: Meeting Program with Titles of Talks and Speaker Schedule
SPONSORS
The meeting gratefully acknowledges the
financial support of the meeting by the following companies:
Abbott Laboratories, Astra Zeneca Pharmaceuticals
LP, Boehringer Ingelheim (Canada), Compaq Computer Corp., Eli Lilly &
Co., Genentech Inc., IBM Life Sciences, Merck Frosst Centre for Therapeutic
Research, Merck Research Laboratories, Novartis Pharma AG, Pfizer Inc.,
Pfizer La Jolla, Pharmacopeia Inc., Roche Bioscience, Schering Plough Research
Institute, Structural GenomiX, and Sunesis Pharmaceuticals.
The meeting was sponsored by the UCSF
Department
of Pharmaceutical Chemistry and the UCSF Molecular
Design Institute. It was co-sponsored by the Biophysical
Society as a satellite meeting of the Year 2002 Annual Biophysical
Society Meeting.
The
UCSF/MDI Scientific Meetings Series
MEETING
MOLECULAR IMAGE
The molecular figure for
the meeting was created by Lillian Chong. It represents the active
site of Methanobacterium thermoautotrophicum orotidine 5'-phosphate
decarboxylase (ODCase), which is occupied by the substrate at a position
inferred by the crystal structure of the inhibitor-bound enzyme.
(Lee, T.S.*; Chong, L.T.*; Chodera,
J.D.; Kollman, P.A. "An Alternative Explanation for the Catalytic Proficiency
of Orotidine 5'-Phosphate Decarbosylase", JACS in press. *These authors
contributed equally to the work.)
top
|
